Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: the GBG 37 ZORO study.
Bernd Gerber, Gunter von Minckwitz, Heinrich Stehle, Toralf Reimer, Ricardo Felberbaum, Nikolai Maass, Dorothea Fischer, Harald L Sommer, Bettina Conrad, Olaf Ortmann, Tanja Fehm, Mahdi Rezai, Keyur Mehta, Sibylle Loibl, undefined German Breast Group Investigators
Journal of Clinical Oncology | Published : 2011
PURPOSE: Observational studies suggested that luteinizing hormone-releasing hormone agonists (LHRHa) might prevent premature ovarian failure resulting from adjuvant chemotherapy in premenopausal patients. We aimed to test the efficacy of ovarian function preservation with the LHRHa goserelin in patients with breast cancer. PATIENTS AND METHODS: In a prospective, randomized, open-label, controlled multicenter study, 60 patients younger than age 46 years with hormone-insensitive breast cancer were allocated to receive anthracycline/cyclophosphamide (with or without taxane) -based neoadjuvant chemotherapy with or without goserelin. The first goserelin injection was administered at least 2 weeks..View full abstract